HOME > TOP STORIES

TOP STORIES

BUSINESS Kite Looks to Expand Japan CAR-T Footprint, Boosts Supply Infrastructure

October 15, 2025
REGULATORY Komeito’s Exit from Ruling Coalition Casts Uncertainty over Japan’s Drug Policy

October 15, 2025
REGULATORY MHLW to Clarify Criteria for Japanese PI Waivers through Q&A, Calls for Data-Based Justifications

October 14, 2025
REGULATORY GS1 Barcode Adoption Stalls at 40% of Hospitals, Pharmacist Urges Subsidies

October 10, 2025
REGULATORY Japan Launches Study on Legal Framework for Patent Linkage System

October 9, 2025
REGULATORY Chuikyo Frowns on Industry Calls for Scrapping Huge-Seller Re-Pricing, Spillovers

October 9, 2025
BUSINESS NHI-Market Price Gap Likely to Narrow Further in 2025; Will It Drop into 4% Zone?

October 8, 2025
BUSINESS Leqembi Iqlik Autoinjector Now Available in US: Eisai/Biogen

October 8, 2025
COMMENTARY Inside Eylea - 2: Will a Bio-AG Return after Six Years? Pricing Debate Resumes

October 7, 2025
ACADEMIA Japan’s Sakaguchi Wins 2025 Nobel Prize in Medicine

October 7, 2025
BUSINESS Pharma Industry Generally Welcomes New LDP Leader Takaichi

October 7, 2025
BUSINESS Boehringer Ingelheim Taps Marc Hasson to Lead Japan Operations

October 7, 2025
COMMENTARY Inside Eylea - 1: Patent Issues Behind Differences in Biosimilar Indications for AMD and DME

October 6, 2025
BUSINESS Moderna Reaffirms Japan Commitment, Denies Downsizing Concerns

October 3, 2025
BUSINESS Regeneron Bolsters Japan Oncology Team as Libtayo Gains Ground

October 3, 2025
BUSINESS Argenx Puts Japan at Core of Global Innovation Strategy

October 3, 2025
BUSINESS Sanofi Sets Sights on 2026 NIP Inclusion of RSV Drug Beyfortus in Japan

October 2, 2025
BUSINESS SSP to Roll Out Pharmacist Training Ahead of OTC Cialis Launch in Japan

October 1, 2025
ORGANIZATION Policy Veterans’ Group Calls for Inflation-Linked Drug Pricing in FY2026 Reform

October 1, 2025
BUSINESS Heartseed, Novo Nordisk End Global Cell Therapy Pact

October 1, 2025

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Pharma Renews Call to Scrap “Spillover,” “Huge-Seller” Rules as FY2026 Talks Enter Final Stretch

By Ken Yoshino

Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…

COMMENTARY

FY2026 Reform Debate for Drug Pricing Nears the Finish Line, Balance Needed

By Takashi Ebisawa

Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…

COLUMN

AI in HR: Navigating the Ethical Minefield

By Philip Carrigan

Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…